Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
February 5, 2022
Sean Bentley, Hewa Artin, Eamonn Mehaffey et al.
Racemic (R,S)‐ketamine is a glutamatergic drug with potent and rapid acting antidepressant effects. An intranasal formulation of (S)‐ketamine was recently approved by the US Food and Drug Administration (FDA) to be used in individuals with treatment‐resistant depression (TRD). There are no data directly comparing outcomes on depression or other comorbidities between these two formulations of...
Frontiers in Psychiatry
January 12, 2022
Shannon Dames, Pamela Kryskow, Crosbie Watler
38 citations
Amid an international pandemic and a worsening mental health crisis, ketamine-assisted therapy is emerging as a promising solution for those deemed “treatment resistant.” Post-traumatic stress disorder (PTSD) and depression are on the rise, with accelerating direct (e.g., burden of suffering) and indirect (e.g., disability/role impairment and impact on family) costs. Psychedelic-assisted...
Frontiers in Psychiatry
2022
Shannon Dames, Pamela Kryskow, Crosbie Watler
correction
Corrigendum: A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers with PTSD and DepressionError in Figure/TableIn the published article, there was an error in Figure 2 as published. The PTSD label on the legend that is imbedded in the figure was on the legend component of the figure was posted on the anxiety...
Frontiers in Psychiatry
2022
Joshua Willms, Ben McCauley, Lindsay Kerr et al.
Suicide is the most common cause of death in male resident physicians and the second most common cause of death in resident physicians overall. Physicians also experience high rates of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and burnout. These conditions frequently develop during medical school, and threaten not only physicians but the patients they care for. A...
Clinical Case Studies
August 1, 2021
Mailae Halstead, Sara Reed, Robert Krause et al.
Current research suggests that ketamine-assisted psychotherapy has benefit for the treatment of mental disorders. We report on the results of ketamine-assisted intensive outpatient psychotherapeutic treatment of a client with treatment-resistant, posttraumatic stress disorder (PTSD) as a result of experiences of racism and childhood sexual abuse. The client’s presenting symptoms included...
Neuroscience & Biobehavioral Reviews
July 1, 2021
Stephen D Worrell, Thomas J Gould
47 citations
Excessive alcohol consumption is involved in 1/10 of deaths of U.S. working-age adults and costs the country around $250,000,000 yearly. While Alcohol Use Disorder (AUD) pathology is complex and involves multiple neurotransmitter systems, changes in synaptic plasticity, hippocampal neurogenesis, and neural connectivity have been implicated in the behavioral characteristics of AUD. Depressed...
medRxiv Preprint Server
June 13, 2021
Rui Du, Kun Niu, Guofang Lu et al.
preprint
The aim of this systematic review and meta-analysis was to examine the efficacy, anti-effect of ketamine (intervention) for post-traumatic stress disorder (PTSD) patients during analgesia proceeding and mental illness treatment methods, in comparison with control (midazolam, opioid, saline or placebo). The bibliographic databases Cochrane, Embase, Pubmed and Web of Science were searched from...
JMIR Research Protocols
May 11, 2021
A. Philipp-Muller, Taras Reshetukha, Gustavo Vazquez et al.
Background Over one third of patients with posttraumatic stress disorder (PTSD) do not respond to current interventions. Ketamine presents a potential treatment option; however, its effects are temporary. Administering ketamine alongside psychotherapy is one potential means of prolonging its effects; however, only a few studies have investigated this treatment method to date, and none have...
medRxiv Preprint Server
April 10, 2021
Agnes Norbury, Sarah B. Rutter, Abigail B. Collins et al.
1 citation
preprint
Promising initial data indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine may be beneficial in post-traumatic stress disorder (PTSD). Here, we explore the neural correlates of ketamine-related changes in PTSD symptoms, using a rich battery of functional imaging data (two emotion-processing tasks and one task-free scan), collected from a subset of participants...
American Journal of Psychiatry
January 5, 2021
Adriana Feder, Sara Costi, Sarah B. Rutter et al.
239 citations
OBJECTIVE Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first...